Joon Ho Moon
Seoul National University · Medicine
About the Lab
Professor Joon Ho Moon's research lab specializes in clinical and translational research focused on metabolic liver diseases, particularly metabolic dysfunction-associated steatotic liver disease (MASLD), and its systemic implications such as cardiovascular disease. The lab also investigates postpartum diabetes risk in women with gestational diabetes, leveraging genetic and clinical factors for early prediction. Additionally, the lab applies advanced imaging techniques—such as PET/CT, MRI, and dual-source CT— to improve risk stratification and diagnostic accuracy in hematologic malignancies (e.g., multiple myeloma) and post-transplant complications like graft-versus-host disease. Their work emphasizes integrating imaging biomarkers with clinical staging systems to enhance prognostic models and patient outcomes.
Research Overview
Research Output Trend
Figures are computed from collected data and may differ slightly.
Selected Papers
15Background The various subcategories under the overarching term of steatotic liver disease (SLD) have been recently proposed by the nomenclature consensus group and endorsed by international academic liver societies. Our aim was to investigate the association between each subtype of SLD and incident cardiovascular disease (CVD) in a nationwide Korean cohort. Methods From a nationwide health screening database from Korea, 351,068 individuals aged 47–86 years between January 1, 2009 and December 3
Gestational diabetes mellitus (GDM), defined as any degree of glucose intolerance with onset or first recognition during pregnancy, is characterized by underlying maternal defects in the β-cell response to insulin during pregnancy. Women with a previous history of GDM have a greater than 7-fold higher risk of developing postpartum diabetes compared with women without GDM. Various risk factors for postpartum diabetes have been identified, including maternal age, glucose levels in pregnancy, famil
A new severity grading system for graft-versus-host disease (GVHD) was established by the National Institutes of Health (NIH) consensus criteria (NCC). However, its prognostic value still needs to be validated. Four hundred twenty-five consecutive patients who survived beyond 100 days after allogeneic stem cell transplantation were reviewed and reclassified using NCC. GVHD-specific survival (GSS) and cumulative incidence of relapse were compared according to the NIH global score at the onset and
Abstract In multiple myeloma (MM), a high number of focal lesions (FL) detected using positron emission tomography/computed tomography (PET/CT) was found to be associated with adverse prognosis. To design a new risk stratification system that combines the Revised International Staging System (R-ISS) with FL, we analyzed the data of 380 patients with newly diagnosed MM (NDMM) who underwent 18 F-fluorodeoxyglucose ( 18 F-FDG) PET/CT upon diagnosis. The K-adaptive partitioning algorithm was adopted
Objective: We wanted to evaluate the image quality, diagnostic accuracy and radiation exposure of 64-slice dual-source CT (DSCT) coronary angiography according to the heart rate in symptomatic patients during daily clinical practice. Materials and Methods: We performed a retrospective search for the DSCT coronary angiography reports of 729 consecutive symptomatic patients. For the 131 patients who underwent invasive coronary angiography, the image quality, the diagnostic performance (sensitivity
BACKGROUND: This study attempted to identify novel prognostic factors in patients with newly diagnosed primary central nervous system lymphoma (PCNSL) using magnetic resonance imaging (MRI). METHODS: We retrospectively evaluated 67 patients diagnosed with central nervous system (CNS) tumors. The enrollment criteria were as follows: i) pathologic diagnosis of CNS lymphoma, ii) no evidence of systemic involvement, iii) no evidence of human immunodeficiency virus-1 infection or other immunodeficien
The occurrence of autoantibodies after allogeneic stem-cell transplantation was found to be related to cGVHD, and patients expressing autoantibodies had a better survival.
In this multicenter phase II study, we evaluated the safety and efficacy of imatinib in patients with steroid-resistant chronic graft-versus-host disease (cGVHD) and evaluated the quality of life (QOL) of the enrolled patients using the Short Form 36 (SF-36) health survey questionnaire. Thirty-six patients who were diagnosed with steroid-refractory cGVHD and treated with imatinib between March 2013 and February 2019 received 100 mg/day of imatinib for 2 weeks. Depending on the patient's conditio
Research Areas
Dive deeper into Joon Ho Moon's research on Nubint
Open this lab's papers in the app to read with AI, summarize, and cite in your writing.